nach oben

Current Cardiovascular Imaging Reports

Erschienen in:

01.04.2017 | Cardiac Magnetic Resonance (E Nagel and V Puntmann, Section Editors)

Quantitative Tissue Characterization in Pediatric Cardiology

verfasst von: Heiner Latus, Inga Voges

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review discusses the cardiovascular magnetic resonance (CMR) myocardial tissue characterization techniques and its applications with a focus on pediatric patients. Delayed enhancement CMR (DE-CMR) is well established to detect focal myocardial fibrosis in the clinical setting but has its limitation in detecting diffuse myocardial disease. Newer mapping techniques allow exact assessment of myocardial relaxation times and their changes in various cardiac pathologies.

Recent Findings

T1 mapping gives new insights in diffuse myocardial disease in pediatric patients with tetralogy of Fallot. T2 mapping seems to be superior to other CMR parameters for identifying myocarditis. Changes in myocardial T2* in thalassemia major can be detected in childhood suggesting that myocardial damage occurs early in life.

Summary

Advanced CMR mapping techniques underlie a rapid development and enable a noninvasive characterization of the myocardium. Although data for young patients are limited, mapping techniques have the potential to become key imaging tools in pediatric patients.

Etesami M, Gilkeson RC, Rajiah P. Utility of late gadolinium enhancement in pediatric cardiac MRI. Pediatr Radiol. 2016;46(8):1096–113. doi:10.1007/s00247-015-3526-2.PubMedCrossRef

Karamitsos TD, Dall’Armellina E, Choudhury RP, Neubauer S. Ischemic heart disease: comprehensive evaluation by cardiovascular magnetic resonance. Am Heart J. 2011;162(1):16–30. doi:10.1016/j.ahj.2011.04.011.PubMedCrossRef

• Rathod RH, Prakash A, Powell AJ, Geva T. Myocardial fibrosis identified by cardiac magnetic resonance late gadolinium enhancement is associated with adverse ventricular mechanics and ventricular tachycardia late after Fontan operation. J Am Coll Cardiol. 2010;55(16):1721–8. doi:10.1016/j.jacc.2009.12.036. Important study assessing the presence of focal myocardial fibrosis in a large cohort of Fontan-patients showing that LGE was associated with adverse single-ventricle mechanics and higher prevalence of ventricular tachycardia.PubMedPubMedCentralCrossRef

Latus H, Gummel K, Klingel K, Moysich A, Khalil M, Mazhari N, et al. Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy. J Cardiovasc Magn Reson. 2015;17:34. doi:10.1186/s12968-015-0142-0.PubMedPubMedCentralCrossRef

Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation. 2006;113(3):405–13. doi:10.1161/CIRCULATIONAHA.105.548727.PubMedCrossRef

Babu-Narayan S. The role of late gadolinium enhancement cardiovascular magnetic resonance in the assessment of congenital and acquired heart disease. Prog Pediatr Cardiol. 2010;28:11–9. doi:10.1016/j.ppedcard.2009.10.006.CrossRef

Wang J, Liu HY, Lv H, Xiang B, Gruwel M, Tomanek B, et al. Identification of chronic myocardial infarction with extracellular or intravascular contrast agents in magnetic resonance imaging. Acta Pharmacol Sin. 2008;29(1):65–73. doi:10.1111/j.1745-7254.2008.00656.x.PubMedCrossRef

Inoue S, Murakami Y, Ochiai K, Kitamura J, Ishibashi Y, Kawamitsu H, et al. The contributory role of interstitial water in Gd-DTPA-enhanced MRI in myocardial infarction. J Magn Reson Imaging. 1999;9(2):215–9.PubMedCrossRef

Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992–2002.PubMedCrossRef

10.

Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, Ralph-Edwards A, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6(5):587–96. doi:10.1016/j.jcmg.2012.09.018.PubMedCrossRef

11.

Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16(1):14–22. doi:10.1093/ehjci/jeu182.PubMedCrossRef

12.

Fratz S, Chung T, Greil GF, Samyn MM, Taylor AM, Valsangiacomo Buechel ER, et al. Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease. J Cardiovasc Magn Reson. 2013;15:51. doi:10.1186/1532-429X-15-51.PubMedPubMedCentralCrossRef

13.

Stirrat J, Rajchl M, Bergin L, Patton DJ, Peters T, White JA. High-resolution 3-dimensional late gadolinium enhancement scar imaging in surgically corrected tetralogy of Fallot: clinical feasibility of volumetric quantification and visualization. J Cardiovasc Magn Reson. 2014;16:76. doi:10.1186/s12968-014-0076-y.PubMedPubMedCentralCrossRef

14.

Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891–903. doi:10.1016/j.jacc.2010.11.013.PubMedCrossRef

15.

Puntmann VO, Peker E, Chandrashekhar Y, Nagel E. T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res. 2016;119(2):277–99. doi:10.1161/CIRCRESAHA.116.307974.PubMedCrossRef

16.

Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92. doi:10.1186/1532-429X-15-92.PubMedPubMedCentralCrossRef

17.

Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 mapping: basic techniques and clinical applications. JACC Cardiovasc Imaging. 2016;9(1):67–81. doi:10.1016/j.jcmg.2015.11.005.PubMedCrossRef

18.

Riesenkampff E, Messroghli DR, Redington AN, Grosse-Wortmann L. Myocardial T1 mapping in pediatric and congenital heart disease. Circ Cardiovasc Imaging. 2015;8(2):e002504. doi:10.1161/CIRCIMAGING.114.002504.PubMedCrossRef

19.

Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117(1):103–14. doi:10.1161/CIRCULATIONAHA.107.702993.PubMedCrossRef

20.

Valente AM, Gauvreau K, Assenza GE, Babu-Narayan SV, Schreier J, Gatzoulis MA, et al. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. 2014;100(3):247–53. doi:10.1136/heartjnl-2013-304958.PubMedCrossRef

21.

Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356(9234):975–81. doi:10.1016/S0140-6736(00)02714-8.PubMedCrossRef

22.

Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG, et al. Preoperative thresholds for mid-to-late haemodynamic and clinical outcomes after pulmonary valve replacement in tetralogy of Fallot. Eur Heart J. 2016;37(10):829–35. doi:10.1093/eurheartj/ehv550.PubMedCrossRef

23.

Wald RM, Haber I, Wald R, Valente AM, Powell AJ, Geva T. Effects of regional dysfunction and late gadolinium enhancement on global right ventricular function and exercise capacity in patients with repaired tetralogy of Fallot. Circulation. 2009;119(10):1370–7. doi:10.1161/CIRCULATIONAHA.108.816546.PubMedPubMedCentralCrossRef

24.

Park SJ, On YK, Kim JS, Park SW, Yang JH, Jun TG, et al. Relation of fragmented QRS complex to right ventricular fibrosis detected by late gadolinium enhancement cardiac magnetic resonance in adults with repaired tetralogy of Fallot. Am J Cardiol. 2012;109(1):110–5. doi:10.1016/j.amjcard.2011.07.070.PubMedCrossRef

25.

Munkhammar P, Carlsson M, Arheden H, Pesonen E. Restrictive right ventricular physiology after tetralogy of Fallot repair is associated with fibrosis of the right ventricular outflow tract visualized on cardiac magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2013;14(10):978–85. doi:10.1093/ehjci/jet009.PubMedCrossRef

26.

•• Chen CA, Dusenbery SM, Valente AM, Powell AJ, Geva T. Myocardial ECV fraction assessed by CMR is associated with type of hemodynamic load and arrhythmia in repaired tetralogy of Fallot. JACC Cardiovasc Imaging. 2016;9(1):1–10. doi:10.1016/j.jcmg.2015.09.011. First study quantifying biventricular ECV in patients after repair of tetralogy of Fallot showing an association between the amount of diffuse myocardial fibrosis and RV volume overload and arrhythmia. A significant correlation was found between RV and LV ECV demonstrating the important role of interventricular interactions in this patient population.PubMedCrossRef

27.

Broberg CS, Huang J, Hogberg I, McLarry J, Woods P, Burchill LJ, et al. Diffuse LV myocardial fibrosis and its clinical associations in adults with repaired tetralogy of Fallot. JACC Cardiovasc Imaging. 2016;9(1):86–7. doi:10.1016/j.jcmg.2015.10.006.PubMedCrossRef

28.

Vejlstrup N, Sorensen K, Mattsson E, Thilen U, Kvidal P, Johansson B, et al. Long-term outcome of Mustard/Senning correction for transposition of the great arteries in Sweden and Denmark. Circulation. 2015;132(8):633–8. doi:10.1161/CIRCULATIONAHA.114.010770.PubMedCrossRef

29.

Wilson NJ, Clarkson PM, Barratt-Boyes BG, Calder AL, Whitlock RM, Easthope RN, et al. Long-term outcome after the mustard repair for simple transposition of the great arteries. 28-year follow-up. J Am Coll Cardiol. 1998;32(3):758–65.PubMedCrossRef

30.

Babu-Narayan SV, Goktekin O, Moon JC, Broberg CS, Pantely GA, Pennell DJ, et al. Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation. 2005;111(16):2091–8. doi:10.1161/01.CIR.0000162463.61626.3B.PubMedCrossRef

31.

Babu-Narayan SV, Prati D, Rydman R, Dimopoulos K, Diller GP, Uebing A, et al. Dyssynchrony and electromechanical delay are associated with focal fibrosis in the systemic right ventricle—insights from echocardiography. Int J Cardiol. 2016;220:382–8. doi:10.1016/j.ijcard.2016.06.090.PubMedCrossRef

32.

Rydman R, Gatzoulis MA, Ho SY, Ernst S, Swan L, Li W, et al. Systemic right ventricular fibrosis detected by cardiovascular magnetic resonance is associated with clinical outcome, mainly new-onset atrial arrhythmia, in patients after atrial redirection surgery for transposition of the great arteries. Circ Cardiovasc Imaging. 2015;8(5). doi:10.1161/CIRCIMAGING.114.002628.

33.

Fratz S, Hauser M, Bengel FM, Hager A, Kaemmerer H, Schwaiger M, et al. Myocardial scars determined by delayed-enhancement magnetic resonance imaging and positron emission tomography are not common in right ventricles with systemic function in long-term follow up. Heart. 2006;92(11):1673–7. doi:10.1136/hrt.2005.086579.PubMedPubMedCentralCrossRef

34.

Shepard CW, Germanakis I, White MT, Powell AJ, Co-Vu J, Geva T. Cardiovascular magnetic resonance findings late after the arterial switch operation. Circ Cardiovasc Imaging. 2016;9(9). doi:10.1161/CIRCIMAGING.116.004618.

35.

Harris DM, Schelbert EB, Wong TC, Cook SC. Myocardial ischemia after arterial switch procedure detected by regadenoson stress cardiac magnetic resonance. Int J Cardiol. 2014;174(1):e16–8. doi:10.1016/j.ijcard.2014.04.014.PubMedCrossRef

36.

Manso B, Castellote A, Dos L, Casaldaliga J. Myocardial perfusion magnetic resonance imaging for detecting coronary function anomalies in asymptomatic paediatric patients with a previous arterial switch operation for the transposition of great arteries. Cardiol Young. 2010;20(4):410–7. doi:10.1017/S1047951109990503.PubMedCrossRef

37.

d’Udekem Y, Iyengar AJ, Cochrane AD, Grigg LE, Ramsay JM, Wheaton GR, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116(11 Suppl):I157–64. doi:10.1161/CIRCULATIONAHA.106.676445.PubMed

38.

Newburger JW, Sleeper LA, Frommelt PC, Pearson GD, Mahle WT, Chen S, et al. Transplantation-free survival and interventions at 3 years in the single ventricle reconstruction trial. Circulation. 2014;129(20):2013–20. doi:10.1161/CIRCULATIONAHA.113.006191.PubMedPubMedCentralCrossRef

39.

Rathod RH, Prakash A, Kim YY, Germanakis IE, Powell AJ, Gauvreau K, et al. Cardiac magnetic resonance parameters predict transplantation-free survival in patients with Fontan circulation. Circ Cardiovasc Imaging. 2014;7(3):502–9. doi:10.1161/CIRCIMAGING.113.001473.PubMedPubMedCentralCrossRef

40.

Chin CW, Messika-Zeitoun D, Shah AS, Lefevre G, Bailleul S, Yeung EN, et al. A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis. Eur Heart J. 2016;37(8):713–23. doi:10.1093/eurheartj/ehv525.PubMedCrossRef

41.

Weidemann F, Herrmann S, Stork S, Niemann M, Frantz S, Lange V, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120(7):577–84. doi:10.1161/CIRCULATIONAHA.108.847772.PubMedCrossRef

42.

Dusenbery SM, Jerosch-Herold M, Rickers C, Colan SD, Geva T, Newburger JW, et al. Myocardial extracellular remodeling is associated with ventricular diastolic dysfunction in children and young adults with congenital aortic stenosis. J Am Coll Cardiol. 2014;63(17):1778–85. doi:10.1016/j.jacc.2013.11.066.PubMedCrossRef

43.

Dusenbery SM, Lunze FI, Jerosch-Herold M, Geva T, Newburger JW, Colan SD, et al. Left ventricular strain and myocardial fibrosis in congenital aortic stenosis. Am J Cardiol. 2015;116(8):1257–62. doi:10.1016/j.amjcard.2015.07.042.PubMedCrossRef

44.

Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867–76. doi:10.1001/jama.296.15.1867.PubMedCrossRef

45.

Everitt MD, Sleeper LA, Lu M, Canter CE, Pahl E, Wilkinson JD, et al. Recovery of echocardiographic function in children with idiopathic dilated cardiomyopathy: results from the Pediatric Cardiomyopathy Registry. J Am Coll Cardiol. 2014. doi:10.1016/j.jacc.2013.11.059.PubMedPubMedCentral

46.

Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48(10):1977–85. doi:10.1016/j.jacc.2006.07.049.PubMedCrossRef

47.

Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(25):2414–21. doi:10.1016/j.jacc.2008.03.018.PubMedPubMedCentralCrossRef

48.

Grosse-Wortmann L, Roche SL, Yoo SJ, Seed M, Kantor P. Early changes in right ventricular function and their clinical consequences in childhood and adolescent dilated cardiomyopathy. Cardiol Young. 2010;20(4):418–25. doi:10.1017/S1047951109990540.PubMedCrossRef

49.

• Banka P, Robinson JD, Uppu SC, Harris MA, Hasbani K, Lai WW, et al. Cardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study. J Cardiovasc Magn Reson. 2015;17:96. doi:10.1186/s12968-015-0201-6. Multicenter study investigating the use of CMR imaging techniques in children and adolescents with myocarditis. CMR had a high sensitivity for the diagnosis of myocarditis, while LGE was used in all patients and was seen in 81% of the patients followed by T2-weighted imaging (74%), early gadolinium enhancement (55%) and first-pass contrast perfusion (8%).PubMedPubMedCentralCrossRef

50.

Sachdeva S, Song X, Dham N, Heath DM, DeBiasi RL. Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol. 2015;115(4):499–504. doi:10.1016/j.amjcard.2014.11.029.PubMedCrossRef

51.

Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(4):475–84. doi:10.1016/j.jcmg.2012.08.019.PubMedCrossRef

52.

Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S, et al. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. JACC Cardiovasc Imaging. 2016;9(1):40–50. doi:10.1016/j.jcmg.2015.12.001.PubMedCrossRef

53.

aus dem Siepen F, Buss SJ, Messroghli D, Andre F, Lossnitzer D, Seitz S, et al. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16(2):210–6. doi:10.1093/ehjci/jeu183.PubMedCrossRef

54.

•• Lurz P, Luecke C, Eitel I, Fohrenbach F, Frank C, Grothoff M, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-Trial. J Am Coll Cardiol. 2016;67(15):1800–11. doi:10.1016/j.jacc.2016.02.013. This prospective study assessed the diagnostic performance of CMR including T1 and T2 mapping in a large cohort of patients with suspected myocarditis using biventricular endomyocardial biopsy as a reference standard. In patients with acute symptoms, T1 and T2 mapping data were superior to the Lake-Louise criteria in confirming or rejecting the diagnosis of acute myocarditis.PubMedCrossRef

55.

• Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, et al. Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging. 2015;8(6). doi:10.1161/CIRCIMAGING.114.003073. This study evaluated the performance of T1 and T2 mapping to identify active myocarditis in patients with recent-onset heart failure and biopsy-proven myocarditis. Global myocardial T2 was the only CMR parameter showing a significant difference between patients with and without active myocarditis. A cutoff value for myocardial T2 of ≥60 ms provided a high sensitivity.

56.

Hinojar R, Foote L, Arroyo Ucar E, Jackson T, Jabbour A, Yu CY, et al. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. JACC Cardiovasc Imaging. 2015;8(1):37–46. doi:10.1016/j.jcmg.2014.07.016.PubMedCrossRef

57.

Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013;382(9908):1889–97. doi:10.1016/S0140-6736(13)61685-2.PubMedPubMedCentralCrossRef

58.

Smith BM, Dorfman AL, Yu S, Russell MW, Agarwal PP, Mahani MG, et al. Clinical significance of late gadolinium enhancement in patients <20 years of age with hypertrophic cardiomyopathy. Am J Cardiol. 2014;113(7):1234–9. doi:10.1016/j.amjcard.2013.12.034.PubMedCrossRef

59.

Spinner JA, Noel CV, Denfield SW, Krishnamurthy R, Jeewa A, Dreyer WJ, et al. Association of late gadolinium enhancement and degree of left ventricular hypertrophy assessed on cardiac magnetic resonance imaging with ventricular tachycardia in children with hypertrophic cardiomyopathy. Am J Cardiol. 2016;117(8):1342–8. doi:10.1016/j.amjcard.2016.01.032.PubMedCrossRef

60.

Hussain T, Dragulescu A, Benson L, Yoo SJ, Meng H, Windram J, et al. Quantification and significance of diffuse myocardial fibrosis and diastolic dysfunction in childhood hypertrophic cardiomyopathy. Pediatr Cardiol. 2015;36(5):970–8. doi:10.1007/s00246-015-1107-7.PubMedCrossRef

61.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95. doi:10.1161/CIRCULATIONAHA.113.007094.PubMedCrossRef

62.

Ellims AH, Iles LM, Ling LH, Chong B, Macciocca I, Slavin GS, et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. Eur Heart J Cardiovasc Imaging. 2014;15(10):1108–16. doi:10.1093/ehjci/jeu077.PubMedCrossRef

63.

Ellims AH, Iles LM, Ling LH, Hare JL, Kaye DM, Taylor AJ. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson. 2012;14:76. doi:10.1186/1532-429X-14-76.PubMedPubMedCentralCrossRef

64.

Dass S, Suttie JJ, Piechnik SK, Ferreira VM, Holloway CJ, Banerjee R, et al. Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(6):726–33. doi:10.1161/CIRCIMAGING.112.976738.PubMedCrossRef

65.

Steen H, Merten C, Refle S, Klingenberg R, Dengler T, Giannitsis E, et al. Prevalence of different gadolinium enhancement patterns in patients after heart transplantation. J Am Coll Cardiol. 2008;52(14):1160–7. doi:10.1016/j.jacc.2008.05.059.PubMedCrossRef

66.

Hussain T, Fenton M, Peel SA, Wiethoff AJ, Taylor A, Muthurangu V, et al. Detection and grading of coronary allograft vasculopathy in children with contrast-enhanced magnetic resonance imaging of the coronary vessel wall. Circ Cardiovasc Imaging. 2013;6(1):91–8. doi:10.1161/CIRCIMAGING.112.975797.PubMedCrossRef

67.

Madani MH, Canter CE, Balzer DT, Watkins MP, Wickline SA. Noninvasive detection of transplant coronary artery disease with contrast-enhanced cardiac MRI in pediatric cardiac transplants. J Heart Lung Transplant. 2012;31(11):1234–5. doi:10.1016/j.healun.2012.06.001.PubMedPubMedCentralCrossRef

68.

Riesenkampff E, Chen CK, Kantor PF, Greenway S, Chaturvedi RR, Yoo SJ, et al. Diffuse myocardial fibrosis in children after heart transplantations: a magnetic resonance T1 mapping study. Transplantation. 2015;99(12):2656–62. doi:10.1097/TP.0000000000000769.PubMedCrossRef

69.

Tacke CE, Romeih S, Kuipers IM, Spijkerboer AM, Groenink M, Kuijpers TW. Evaluation of cardiac function by magnetic resonance imaging during the follow-up of patients with Kawasaki disease. Circ Cardiovasc Imaging. 2013;6(1):67–73. doi:10.1161/CIRCIMAGING.112.976969.PubMedCrossRef

70.

Fratz S, Hager A, Schreiber C, Schwaiger M, Hess J, Stern HC. Long-term myocardial scarring after operation for anomalous left coronary artery from the pulmonary artery. Ann Thorac Surg. 2011;92(5):1761–5. doi:10.1016/j.athoracsur.2011.06.021.PubMedCrossRef

71.

Latus H, Gummel K, Rupp S, Mueller M, Jux C, Kerst G, et al. Cardiovascular magnetic resonance assessment of ventricular function and myocardial scarring before and early after repair of anomalous left coronary artery from the pulmonary artery. J Cardiovasc Magn Reson. 2014;16(1):3. doi:10.1186/1532-429X-16-3.PubMedPubMedCentralCrossRef

72.

Secinaro A, Ntsinjana H, Tann O, Schuler PK, Muthurangu V, Hughes M, et al. Cardiovascular magnetic resonance findings in repaired anomalous left coronary artery to pulmonary artery connection (ALCAPA). J Cardiovasc Magn Reson. 2011;13:27. doi:10.1186/1532-429X-13-27.PubMedPubMedCentralCrossRef

73.

Puranik R, Tsang VT, Broadley A, Nordmeyer J, Lurz P, Muthialu N, et al. Functional outcomes after the Ross (pulmonary autograft) procedure assessed with magnetic resonance imaging and cardiopulmonary exercise testing. Heart. 2010;96(4):304–8. doi:10.1136/hrt.2009.172965.PubMedCrossRef

74.

Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808–15. doi:10.1056/NEJM199103213241205.PubMedCrossRef

75.

Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN, et al. Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2016;9(12). doi:10.1161/CIRCIMAGING.115.003584.

76.

Tham EB, Haykowsky MJ, Chow K, Spavor M, Kaneko S, Khoo NS, et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson. 2013;15:48. doi:10.1186/1532-429X-15-48.PubMedPubMedCentralCrossRef

77.

Toro-Salazar OH, Gillan E, O’Loughlin MT, Burke GS, Ferranti J, Stainsby J, et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging. 2013;6(6):873–80. doi:10.1161/CIRCIMAGING.113.000798.PubMedCrossRef

78.

Ylanen K, Poutanen T, Savikurki-Heikkila P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol. 2013;61(14):1539–47. doi:10.1016/j.jacc.2013.01.019.PubMedCrossRef

79.

Salerno M, Kramer CM. Advances in parametric mapping with CMR imaging. JACC Cardiovasc Imaging. 2013;6(7):806–22. doi:10.1016/j.jcmg.2013.05.005.PubMedPubMedCentralCrossRef

80.

Abdel-Aty H, Cocker M, Meek C, Tyberg JV, Friedrich MG. Edema as a very early marker for acute myocardial ischemia: a cardiovascular magnetic resonance study. J Am Coll Cardiol. 2009;53(14):1194–201. doi:10.1016/j.jacc.2008.10.065.PubMedCrossRef

81.

Eitel I, Friedrich MG. T2-weighted cardiovascular magnetic resonance in acute cardiac disease. J Cardiovasc Magn Reson. 2011;13:13. doi:10.1186/1532-429X-13-13.PubMedPubMedCentralCrossRef

82.

Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56. doi:10.1186/1532-429X-11-56.PubMedPubMedCentralCrossRef

83.

Wassmuth R, Schulz-Menger J. T2-mapping—clinical experience. Curr Cardiovasc Imaging Rep. 2014;7:9251. doi:10.1007/s12410-013-9251-z.CrossRef

84.

•• Luetkens JA, Homsi R, Dabir D, Kuetting DL, Marx C, Doerner J, et al. Comprehensive cardiac magnetic resonance for short-term follow-up in acute myocarditis. J Am Heart Assoc. 2016;5(7). doi:10.1161/JAHA.116.003603. In this study, traditional CMR parameters and new mapping techniques were used to visualize myocardial tissue inflammation in patients with suspected myocarditis. T1 and T2 mapping showed the best diagnostic performance and when combining both with late gadolinium enhancement imaging they were able to improve the diagnostic performance of established Lake-Louise Criteria.

85.

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87. doi:10.1016/j.jacc.2009.02.007.PubMedPubMedCentralCrossRef

86.

Luetkens JA, Homsi R, Sprinkart AM, Doerner J, Dabir D, Kuetting DL, et al. Incremental value of quantitative CMR including parametric mapping for the diagnosis of acute myocarditis. Eur Heart J Cardiovasc Imaging. 2016;17(2):154–61. doi:10.1093/ehjci/jev246.PubMedCrossRef

87.

Thavendiranathan P, Walls M, Giri S, Verhaert D, Rajagopalan S, Moore S, et al. Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping. Circ Cardiovasc Imaging. 2012;5(1):102–10. doi:10.1161/CIRCIMAGING.111.967836.PubMedCrossRef

88.

Zhang Y, Corona-Villalobos CP, Kiani AN, Eng J, Kamel IR, Zimmerman SL, et al. Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging. 2015;31(2):389–97. doi:10.1007/s10554-014-0560-3.PubMedCrossRef

89.

Markl M, Rustogi R, Galizia M, Goyal A, Collins J, Usman A, et al. Myocardial T2-mapping and velocity mapping: changes in regional left ventricular structure and function after heart transplantation. Magn Reson Med. 2013;70(2):517–26. doi:10.1002/mrm.24472.PubMedCrossRef

90.

Usman AA, Taimen K, Wasielewski M, McDonald J, Shah S, Giri S, et al. Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging. 2012;5(6):782–90. doi:10.1161/CIRCIMAGING.111.971101.PubMedCrossRef

91.

Nishii T, Kono AK, Shigeru M, Takamine S, Fujiwara S, Kyotani K, et al. Cardiovascular magnetic resonance T2 mapping can detect myocardial edema in idiopathic dilated cardiomyopathy. Int J Cardiovasc Imaging. 2014;30 Suppl 1:65–72. doi:10.1007/s10554-014-0414-z.PubMedCrossRef

92.

Amano Y, Aita K, Yamada F, Kitamura M, Kumita S. Distribution and clinical significance of high signal intensity of the myocardium on T2-weighted images in 2 phenotypes of hypertrophic cardiomyopathy. J Comput Assist Tomogr. 2015;39(6):951–5. doi:10.1097/RCT.0000000000000296.PubMedCrossRef

93.

Ito T, KK A, Takamine S, Shigeru M, Mori S, Takaya T, et al. A comparison of quantitative T2 mapping on cardiovascular magnetic resonance imaging with metaiodobenzylguanidine scintigraphy and left ventricular functional recovery in dilated cardiomyopathy: a retrospective pilot study. Intern Med. 2015;54(17):2121–8. doi:10.2169/internalmedicine.54.4493.PubMedCrossRef

94.

Lee KH, Park HS, Park CH, Kim KH, Chung H, Kim TH, et al. Extracellular volume imaging and quantitative T2 mapping for the diagnosis of mitochondrial cardiomyopathy. Circulation. 2014;130(20):1832–4. doi:10.1161/CIRCULATIONAHA.114.010779.PubMedCrossRef

95.

Wansapura JP, Hor KN, Mazur W, Fleck R, Hagenbuch S, Benson DW, et al. Left ventricular T2 distribution in Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2010;12:14. doi:10.1186/1532-429X-12-14.PubMedPubMedCentralCrossRef

96.

Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128(3):281–308. doi:10.1161/CIR.0b013e31829b2be6.PubMedCrossRef

97.

Chavhan GB, Babyn PS, Thomas B, Shroff MM, Haacke EM. Principles, techniques, and applications of T2*-based MR imaging and its special applications. Radiographics. 2009;29(5):1433–49. doi:10.1148/rg.295095034.PubMedPubMedCentralCrossRef

98.

Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33–9. doi:10.1002/jmri.10332.PubMedCrossRef

99.

Smith GC, Carpenter JP, He T, Alam MH, Firmin DN, Pennell DJ. Value of black blood T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:21. doi:10.1186/1532-429X-13-21.PubMedPubMedCentralCrossRef

100.

Salerno M, Janardhanan R, Jiji RS, Brooks J, Adenaw N, Mehta B, et al. Comparison of methods for determining the partition coefficient of gadolinium in the myocardium using T1 mapping. J Magn Reson Imaging. 2013;38(1):217–24. doi:10.1002/jmri.23875.PubMedCrossRef

101.

Captur G, Manisty C, Moon JC. Cardiac MRI evaluation of myocardial disease. Heart. 2016;102(18):1429–35. doi:10.1136/heartjnl-2015-309077.PubMedCrossRef

102.

Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051–2. doi:10.1016/S0140-6736(00)02357-6.PubMedCrossRef

103.

Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WW, et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32(2):315–9. doi:10.1002/jmri.22245.PubMedPubMedCentralCrossRef

104.

Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–8. doi:10.1161/CIRCULATIONAHA.109.874487.PubMedPubMedCentralCrossRef

105.

• Casale M, Meloni A, Filosa A, Cuccia L, Caruso V, Palazzi G, et al. Multiparametric cardiac magnetic resonance survey in children with thalassemia major: a multicenter study. Circ Cardiovasc Imaging. 2015;8(8):e003230. doi:10.1161/CIRCIMAGING.115.003230. This multicentre and multiparametric study included the largest cohort of pediatric thalassaemia major patients. It shows that myocardial iron overload can occur early in childhood suggesting that MRI T2* imaging should be performed regularly in pediatric thalassaemia major patients.

106.

Borgna-Pignatti C, Meloni A, Guerrini G, Gulino L, Filosa A, Ruffo GB, et al. Myocardial iron overload in thalassaemia major. How early to check? Br J Haematol. 2014;164(4):579–85. doi:10.1111/bjh.12643.PubMedCrossRef

107.

Kaushik N, Eckrich MJ, Parra D, Yang E. Chronically transfused pediatric sickle cell patients are protected from cardiac iron overload. Pediatr Hematol Oncol. 2012;29(3):254–60. doi:10.3109/08880018.2011.630774.PubMedCrossRef

108.

Badawy SM, Liem RI, Rigsby CK, Labotka RJ, DeFreitas RA, Thompson AA. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease. Br J Haematol. 2016. doi:10.1111/bjh.14277.PubMed

109.

Meloni A, Puliyel M, Pepe A, Berdoukas V, Coates TD, Wood JC. Cardiac iron overload in sickle-cell disease. Am J Hematol. 2014;89(7):678–83. doi:10.1002/ajh.23721.PubMedCrossRef

110.

Berdoukas V, Nord A, Carson S, Puliyel M, Hofstra T, Wood J, et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. Am J Hematol. 2013;88(11):E283–5. doi:10.1002/ajh.23543.PubMedCrossRef

111.

Fletcher LM, Halliday JW. Haemochromatosis: understanding the mechanism of disease and implications for diagnosis and patient management following the recent cloning of novel genes involved in iron metabolism. J Intern Med. 2002;251(3):181–92.PubMedCrossRef

112.

Carpenter JP, Grasso AE, Porter JB, Shah F, Dooley J, Pennell DJ. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson. 2013;15:24. doi:10.1186/1532-429X-15-24.PubMedPubMedCentralCrossRef

Titel: Quantitative Tissue Characterization in Pediatric Cardiology
verfasst von: Heiner Latus
Inga Voges
Publikationsdatum: 01.04.2017
Verlag: Springer US
Erschienen in: Current Cardiovascular Imaging Reports / Ausgabe 4/2017
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-017-9405-5

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen